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Reduced Expression of Nuclear-Encoded Genes Involved
in Mitochondrial Oxidative Metabolism in Skeletal
Muscle of Insulin-Resistant Women With Polycystic Ovary
Syndrome
Vibe Skov,1 Dorte Glintborg,2 Steen Knudsen,3 Thomas Jensen,3 Torben A. Kruse,1 Qihua Tan,1,4
Klaus Brusgaard,1 Henning Beck-Nielsen,2 and Kurt Højlund2
Insulin resistance in skeletal muscle is a major risk factor
for the development of type 2 diabetes in women with
polycystic ovary syndrome (PCOS). In patients with type 2
diabetes, insulin resistance in skeletal muscle is associated
with abnormalities in insulin signaling, fatty acid metabo-
lism, and mitochondrial oxidative phosphorylation (OX-
PHOS). In PCOS patients, the molecular mechanisms of
insulin resistance are, however, less well characterized. To
identify biological pathways of importance for the patho-
genesis of insulin resistance in PCOS, we compared gene
expression in skeletal muscle of metabolically character-
ized PCOS patients (n  16) and healthy control subjects
(n 13) using two different approaches for global pathway
analysis: gene set enrichment analysis (GSEA 1.0) and
gene map annotator and pathway profiler (GenMAPP 2.0).
We demonstrate that impaired insulin-stimulated total,
oxidative and nonoxidative glucose disposal in PCOS pa-
tients are associated with a consistent downregulation of
OXPHOS gene expression using GSEA and GenMAPP anal-
ysis. Quantitative real-time PCR analysis validated these
findings and showed that reduced levels of peroxisome
proliferator–activated receptor  coactivator  (PGC-1)
could play a role in the downregulation of OXPHOS genes
in PCOS. In these women with PCOS, the decrease in
OXPHOS gene expression in skeletal muscle cannot be
ascribed to obesity and diabetes. This supports the hypoth-
esis of an early association between insulin resistance and
impaired mitochondrial oxidative metabolism, which is, in
part, mediated by reduced PGC-1 levels. These abnormal-
ities may contribute to the increased risk of type 2 diabetes
observed in women with PCOS. Diabetes 56:2349–2355,
2007
Polycystic ovary syndrome (PCOS) is a commonendocrine disorder affecting 5–10% of reproduc-tive-aged women (1). It is a heterogeneous con-dition with unknown etiology characterized by
hyperandrogenism and anovulatory infertility and occurs
in association with insulin resistance leading to compen-
satory hyperinsulinemia, which stimulates ovarian andro-
gen production (1,2). Insulin resistance in PCOS patients
confers a substantial risk for developing type 2 diabetes
and cardiovascular disease (1–4), and the increase in
incidence of PCOS parallels the increase in obesity making
it an important threat to the Western world and developing
countries in the future (1).
Skeletal muscle is the major site of insulin-stimulated
glucose disposal (5), and muscular insulin resistance in
this tissue therefore represents a major risk factor for type
2 diabetes in PCOS patients. This is reflected by impaired
insulin-stimulated total, oxidative, and nonoxidative glu-
cose disposal in PCOS (6) similar to the defects observed
in type 2 diabetes (7,8). The mechanisms underlying
skeletal muscle insulin resistance in PCOS in vivo are
largely unknown but may include reduced insulin-medi-
ated association of phosphatidylinositol 3-kinase (PI 3-
kinase) with insulin receptor substrate-1 (IRS-1) and
increased serine phosphorylation of the insulin receptor
and IRS-1 (9–13). Similar abnormalities have been re-
ported in skeletal muscle of patients with type 2 diabetes
(7,8), but insulin resistance in patients with type 2
diabetes and their first-degree relatives is further char-
acterized by impaired insulin activation of glycogen
synthase (14), increased lipid content (15), and abnor-
malities in mitochondrial oxidative phosphorylation
(OXPHOS) in skeletal muscle (16 –22). Whether these
abnormalities also exist in skeletal muscle from PCOS
patients remains to be examined.
High-throughput technologies, such as DNA microar-
rays, are powerful tools that enable researchers to deter-
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mine changes in transcript levels of thousands of genes
simultaneously (23). Because many genes are dysregu-
lated during the development and progression of a com-
plex disease, biological pathway analyses using data from
DNA microarray experiments may lead to a more compre-
hensive understanding of a disease at the molecular level.
Recently, application of transcriptomics and proteomics in
diabetes research has pointed to abnormalities in mito-
chondrial metabolism in skeletal muscle (19–22) and
indicated that reduced expression of peroxisome prolif-
erator–activated receptor  coactivator-1 (PGC-1) and -1
(PGC-1) and nuclear respiratory factor 1 (NRF-1) could play
a key role for these changes in insulin-resistant muscle
(21,22). Whether insulin resistance in patients with PCOS is
associated with the same or unique transcriptional changes
in skeletal muscle remains to be determined.
To identify biological pathways in skeletal muscle asso-
ciated with insulin resistance in PCOS, we applied high-
density oligonucleotide arrays, two different approaches
for global pathway analysis, and quantitative real-time
PCR to compare gene expression profiles in skeletal
muscle of insulin-resistant women with PCOS and well-
matched healthy control women who were metabolically
characterized by euglycemic-hyperinsulinemic clamp and
indirect calorimetry.
RESEARCH DESIGN AND METHODS
Subjects, metabolic characterization, and muscle biopsy. Sixteen obese
women of fertile age with PCOS and 13 healthy women, matched according to
age and BMI, participated in the study (Table 1). These subjects were selected
from a larger cohort who participated in a study reported recently (6). The
subpopulation of PCOS patients represents the most insulin-resistant subjects
from whom a basal muscle biopsy were obtained. Inclusion and exclusion
criteria for PCOS and control subjects are as described previously (6). In brief,
criteria for PCOS included oligoovulation (defined as irregular periods during
1 year in combination with a cycle length of 35 days), elevated free
testosterone levels (0.035 nmol/l), and/or hirsutism (total Ferriman-Gallwey
score 7) and the absence of diabetes, hypertension, hyperprolactinemia,
hypothyroidism, and adrenal enzyme defects. All PCOS subjects had A1C
within the normal range (4.9–6.1%). Control subjects had regular menses,
normal glucose tolerance, and no family history of diabetes. No subjects were
taking medicines known to affect hormonal or metabolic parameters. In-
formed written consent was obtained from all subjects before participation.
The study was approved by the local ethics committee and was performed in
accordance with the Helsinki Declaration.
The euglycemic-hyperinsulinemic clamp studies were performed after an
overnight fast as described in detail previously (6). In brief, a 2-h basal tracer
equilibration period was followed by infusion of insulin at a rate of 40 mU 
m2  min1 for 3 h. The studies were combined with indirect calorimetry, and
rates of total glucose disposal, glucose and lipid oxidation, and nonoxidative
glucose metabolism were calculated as described previously (6). A muscle
biopsy from each subject was obtained from the vastus lateralis muscle in the
basal state after the 2-h basal tracer equilibration period using a modified
Bergstro¨m needle with suction under local anesthesia. Muscle samples were
immediately frozen in liquid nitrogen within 30 s. Serum levels of insulin, free
testosterone, luteinizing hormone (LH), follicle-stimulating hormone (FSH),
and plasma glucose, triglyceride, and free fatty acids (FFAs) were assayed as
described previously (6).
RNA extraction. Frozen muscle tissue was homogenized in Trizol with a
Polytron Homogenizer, and total RNA was purified using TRIzol Reagent (Life
Technologies, Gaithersburg, MD), including an extra step after phase separa-
tion with chloroform. Briefly, 1 vol phenol-chloroform-isoamylalcohol (25-
24-1) (Sigma-Aldrich, St. Louis, MO) was added to the aqueous phase and spun
at 12,000 rpm for 20 min at 4°C. Then, 1 vol chloroform was added to the
aqueous phase and spun at 12,000 rpm for 20 min at 4°C. Quantity of RNA was
determined with a spectrophotometer, and RNA integrity was assessed using
Agilent 2100 Bioanalyser and degradometer software (24).
Amplified RNA preparation and microarray hybridization. One g
purified total RNA was converted to biotin-labeled aRNA using the Message-
AmpTM II-Biotin single-round amplified RNA (aRNA) amplification kit accord-
ing to the manufacturer’s instructions (Ambion, Austin, TX). Labeled aRNA
was fragmented as described in the Affymetrix manual (Affymetrix, Santa
Clara, CA) and hybridized to Affymetrix HG-U133 Plus 2.0 chips. All glyceral-
dehyde-3-phosphate dehydrogenase (GAPDH) 3	/5	 probe set hybridization
ratios range from 0.92 to 1.42.
Data treatment and statistical analysis. The R statistical software (25)
was applied for initial data processing and statistical analysis. Global back-
ground correction of probe intensities was performed using a method
implemented in the robust multi-array average method (26), and nonlinear
normalization of probe intensities was done using qspline (27). Gene expres-
sion index calculation was done using model-based index calculation (28).
Only perfect-match probes were included in data analysis. Differences in gene
expression between groups were calculated for each gene in the dataset by
using Welch two sample t test. An uncorrected P  0.05 was considered
significant.
Global pathway analyses. Gene expression changes were integrated with
gene sets and biological pathways using gene map annotator and pathway
profiler (GenMAPP 2.0) (29) and gene set enrichment analysis (GSEA 1.0)
(30). MAPPFinder 2.0 (31), a tool integrated in GenMAPP 2.0, was applied to
examine significant pathways and gene ontology terms. In GSEA, a total of 169
gene sets were applied. All genes were ranked according to changes in gene
expression between PCOS patients and control subjects using the t test in the
GSEA software. Ten thousand gene permutations were used to obtain the
nominal P value, and gene sets with a false discovery rate (FDR) 0.05 were
suggested to be significantly regulated.
Quantitative real-time PCR. DNase I–treated RNA from 13 PCOS patients
and 13 control subjects was reverse transcribed to single-stranded cDNA
using TaqMan reverse transcription reagents and random hexamer primers
(Applied Biosystems). Three women with PCOS were not included in the
analysis because of a lack of RNA. TaqMan gene expression assays (Applied
Biosystems) for nine selected genes (Supplemental Table 1, which is detailed
in the online appendix [available at http://dx.doi.org/10.2337/db07-0275]) and
TaqMan Universal Master Mix (Applied Biosystems) were used for quantifi-
cation of gene expression using Applied Biosystems Prism 7700. Expression of
target genes was normalized to the endogenous controls PPIA (cyclophilin A)
and GAPDH. To perform the most appropriate validation of microarray data,
bioinformatic approaches, such as NetAffx (http://www.Affymetrix.com), ref-
seq (http://www.ncbi.nlm.nih.gov), and Ensembl (http://www.ensembl.org),
were used to identify the Affymetrix probe set for each gene with the highest
similarity to the TaqMan probe sequence (Supplemental Table 1).
RESULTS
Clinical and metabolic characteristics of the study sub-
jects are presented in Table 1. Fasting levels of serum
insulin, free testosterone, LH-to-FSH ratio, and plasma
free triglycerides were elevated in women with PCOS
compared with control subjects (P  0.01). No difference
TABLE 1
Clinical and metabolic characteristics
PCOS
patients
Control
subjects
n 16 13
Age (years) 30.8 
 1.8 34.7 
 2.0
BMI (kg/m2) 34.1 
 1.1 34.0 
 1.8
Plasma glucose (mmol/l) 5.5 
 0.1 5.5 
 0.1
Serum insulin (pmol/l) 116 
 16 43 
 4*
Plasma triglycerides (mmol/l) 1.95 
 0.23 0.86 
 0.12*
Serum-free testosterone (mg/l) 0.17 
 0.03 0.06 
 0.01*
Serum LH-to-FSH ratio 1.55 
 0.17 0.68 
 0.06*
Plasma FFA (mmol/l) 0.47 
 0.03 0.49 
 0.04
Plasma FFA during clamp (mmol/l) 0.07 
 0.01 0.02 
 0.00*
Total glucose disposal during clamp
(mg  m2  min1)
121 
 4 289 
 23*
Glucose oxidation during clamp
(mg  m2  min1)
76 
 5 124 
 5*
Nonoxidative glucose metabolism
during clamp (mg  m2  min1)
45 
 5 165 
 22*
Lipid oxidation during clamp
(mg  m2  min1)
26 
 2 7 
 2*
Data are means 
 SEM. *P  0.01 PCOS vs. control subjects.
Students t test for nonpaired data was used.
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in fasting plasma glucose or FFA levels was observed. In
the basal state, rates of glucose and lipid metabolism were
similar in the groups (data not shown). During the insulin-
stimulated period, total glucose disposal was 58% lower in
women with PCOS than in control subjects (P 0.01), and
this was primarily accounted for by a 72% reduction in
nonoxidative glucose metabolism (P  0.01), but also a
39% decrease in glucose oxidation (P  0.01). Moreover,
the ability of insulin to suppress lipid oxidation and
plasma FFA levels was impaired in PCOS patients com-
pared with control subjects (P  0.01).
Gene expression analysis. By applying the R statistical
software, we found that of the 54,675 transcripts repre-
sented on the array, 3,730 transcripts were downregulated
and 2,407 were upregulated in skeletal muscle of PCOS
patients compared with control subjects (uncorrected P
0.05). Only 34 probe sets with a fold change ranging from
1.09 to 1.47 for downregulated genes and from 1.12 to
1.85 for upregulated genes (Supplemental Table 2) re-
mained differentially expressed after controlling for mul-
tiple hypothesis testing using the Benjamini-Hochberg
method (FDR 0.1) (32). Nearly one-half of these probe
sets had unknown function, and the remaining probe sets
did not appear to be of interest in the study of the
pathogenesis of insulin resistance in PCOS.
Global pathway analysis revealed decreased expres-
sion of OXPHOS genes. We applied two pathway pro-
grams, GenMAPP 2.0 and GSEA 1.0, to perform a general
search for pathways associated with insulin resistance in
skeletal muscle of PCOS patients. Using MAPPFinder 2.0,
the significantly downregulated pathways in muscle of
PCOS patients were the electron transport chain, trans-
forming growth factor- signaling pathway, G-protein sig-
naling, calcium regulation in cardiac cells, adipogenesis,
and insulin signaling (z  2.0) (Table 2). Nine pathways
were significantly upregulated, and the 10th most upregu-
lated pathway was insulin signaling (z  1.7) (Table 3).
Interestingly, two pathways, insulin signaling and calcium
regulation in cardiac cells, were found among the top 10 of
both the up- and downregulated pathways. We could not
find evidence that a specific subgroup of genes involved in
insulin signaling to glucose metabolism, protein synthesis,
or mitogenesis was unambiguously regulated in one direc-
tion. Similarly, the genes involved in calcium regulation
did not point to specific subgroups of down- or upregu-
lated genes. When evaluating the family-wise error rate
(FWER) values for up- and downregulated pathways, only
the electron transport chain remained significant. In gene
ontology, oxidoreductase activity/acting on NADH or
NADPH and closely related pathways were the most
TABLE 2
Ranking of the 10 most downregulated pathways analyzed with MAPPFinder 2.0
MAPP name
Changed
(n)*
Measured
(n)†
On MAPP
(n)‡
Changed
(%)§ z score
Permute
P value
FWER
P value
Electron transport chain 35 91 105 38.46 6.39 0.0005 0.0005
Transforming growth factor- signaling pathway 16 52 52 30.77 3.23 0.003 0.154
G-protein signaling 22 92 92 23.91 2.46 0.013 0.688
Calcium regulation in cardiac cells 32 149 149 21.48 2.23 0.024 0.8
Adipogenesis 28 130 131 21.54 2.20 0.037 0.858
Insulin signaling 33 159 159 20.75 2.12 0.038 0.871
Fas pathway and stress induction of heat shock
protein regulation 10 38 38 26.32 1.98 0.06 0.963
Smooth muscle contraction 31 155 156 20.00 1.82 0.074 0.985
Hs G1 to S cell cycle reactome 15 67 67 22.39 1.73 0.091 0.998
Complement activation classical 5 17 17 29.41 1.68 0.151 1
A fold change1.05 and a P value0.05 were used as the criteria for gene expression changes between PCOS patients and control subjects.
The statistical rating of the relative gene expression activity was provided by the z score. The z score was based on N  3,196 genes linked
to local MAPPs and R  477 of these genes meeting the criteria for change in expression. *Number of genes changed. †Number of genes
measured on the chip. ‡Number of genes on the MAPP. §Number changed divided by number measured.
TABLE 3
The 10 most upregulated pathways analyzed with MAPPFinder 2.0
MAPP name
Changed
(n)*
Measured
(n)†
On MAPP
(n)‡
Changed
(%)§ z score
Permute
P value
FWER
P value
Integrin-mediated cell adhesion 21 98 99 21.43 3.39 0.003 0.161
Signaling of hepatocyte growth factor receptor 9 32 34 28.13 3.14 0.002 0.225
Regulation of actin cytoskeleton 26 142 146 18.31 2.89 0.002 0.342
Apoptosis 16 82 82 19.51 2.53 0.013 0.616
Tissues (muscle, fat, and connective) 16 82 84 19.51 2.53 0.015 0.616
Calcium regulation in cardiac cells 25 149 149 16.78 2.35 0.023 0.772
Glycogen metabolism 8 36 36 22.22 2.19 0.037 0.861
Smooth muscle contraction 25 155 156 16.13 2.13 0.039 0.888
Striated muscle contraction 8 38 38 21.05 2.01 0.066 0.944
Insulin signaling 24 159 159 15.09 1.73 0.092 0.989
A fold change 1.05 and a P value 0.05 were used as the criteria for gene expression changes between PCOS patients and control subjects.
The statistical rating of the relative gene expression activity was provided by the z score. The z score was based on N  3,196 genes linked
to a MAPP and R 349 of these genes meeting the criteria for change in expression. *Number of genes changed. †Number of genes measured
on the chip. ‡Number of genes on the MAPP. §Number changed divided by number measured.
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significantly downregulated molecular function terms. Of
interest, calcium ion transporter activity was the fourth
most downregulated molecular function term, further in-
dicating a role for calcium regulation in muscle of women
with PCOS. Mitochondrion was the most downregulated
cellular component, and mitochondrial electron transport/
ubiquinol to cytochrome c was the most downregulated
biological process (Supplemental Table 3). Upregulated
gene ontology terms are depicted in Supplemental Table 4.
Applying GSEA on the same dataset, we found that only
the gene sets VOXPHOS and electron transport chain were
significantly downregulated (FDR 0.05). Moreover, the
gene sets termed mitochondria and human mitoDB 6 2002
were among the 10 most downregulated pathways. Fatty
acid metabolism was the third most downregulated path-
way, and another fatty acid metabolism gene set was the
sixth most downregulated pathway (Table 4). No gene sets
were significantly upregulated (FDR 0.05) (Supplemen-
tal Table 5). Taking the FWER P value into account, only
the VOXPHOS and electron transport chain gene sets
remained significant. When evaluating the results from
GenMAPP and GSEA, pathways representing OXPHOS
genes were consistently downregulated, even when using
the very stringent FWER P value.
Decreased expression of OXPHOS genes validated by
quantitative real-time PCR. Earlier studies have impli-
cated a role for alterations in OXPHOS in insulin resis-
tance. Using two approaches for global pathway analysis
of muscle transcripts, we consistently observed a down-
regulation of nuclear-encoded OXPHOS genes in muscle of
PCOS patients. We therefore focused on this pathway in
further analyses. To validate our microarray data, we used
quantitative real-time PCR to examine gene expression
levels of one gene from each of the five respiratory
complexes (I–V) (NDUFA3, SDHD, UCRC, COX7C, and
ATP5H) and one uncoupling protein (UCP2). In the mi-
croarray experiment, these genes were all downregulated
at the single-gene level (uncorrected P  0.05) in muscle
from PCOS patients. Moreover, we studied gene expres-
sion of PGC-1, PGC-1, and NRF-1, which are known to
be involved in the transcriptional control of mitochondrial
biogenesis. In accordance with the results obtained from
microarray analysis, the expression of four of five respira-
tory genes together with the expression of UCP2 was
significantly downregulated in PCOS patients compared
with control subjects (P  0.05). Moreover, PGC1- ex-
pression was significantly reduced in PCOS patients com-
pared with control subjects (P  0.01) (Fig. 1). No
differences with respect to expression of PGC-1 and
NRF-1 were found.
To explore the potential relationship between mRNA
levels of PGC-1 and downregulation of OXPHOS genes,
we performed simple correlation analysis. In the total
population, PGC-1 mRNA levels correlated strongly with
the expression of each of the five OXPHOS genes studied
(r  0.59–0.89; all P  0.001) but not with UCP2 mRNA
levels. In control subjects, the relationship between
PGC-1 mRNA levels and expression of ATP5H, NDUFA3,
and UCRC was preserved (all P  0.05); whereas in PCOS
patients, only NDUFA3 expression (P  0.01) showed a
significant association with PGC-1 levels.
DISCUSSION
Previous studies of insulin resistance in skeletal muscle of
women with PCOS have focused on individual proteins
and genes involved in insulin signaling (9–13). Using
global approaches, such as transcriptomics and proteom-
ics, it is possible to study the profile of a large number of
distinct genes and proteins simultaneously. In the present
FIG. 1. Relative expression of nine selected genes in skeletal muscle of
PCOS patients (n  13) vs. control subjects (n  13) determined by
quantitative real-time PCR. Downregulated genes in PCOS patients
have mRNA levels <1.0 (dotted line), and upregulated genes have
mRNA levels >1.0. Data are means  SE. *P < 0.05 PCOS vs. control
subjects.
TABLE 4
The 10 most downregulated gene sets ranked according to the normalized enrichment score using GSEA 1.0
Name SIZE ES NES NOM P value FDR q value FWER P value
VOXPHOS 84 0.50 2.05 0.0001 0.001 0.001
Electron transport chain 92 0.49 2.04 0.0001 0.001 0.003
Fatty acid metabolism 25 0.51 1.65 0.011 0.130 0.531
MAP00280 valine, leucine, and isoleucine
degradation 26 0.46 1.49 0.033 0.387 0.957
MAP00350 tyrosine metabolism 30 0.43 1.45 0.060 0.448 0.995
MAP00071 fatty acid metabolism 45 0.39 1.41 0.057 0.515 0.999
Mitochondria 437 0.28 1.37 0.004 0.579 1.000
hTERT DN 66 0.36 1.37 0.056 0.511 1.000
Human mitoDB 6 2002 412 0.28 1.35 0.007 0.506 1.000
CR repair 39 0.38 1.33 0.105 0.543 1.000
All genes on the chip were ranked by difference in expression between PCOS patients and control subjects using the t test. An enrichment
score (ES) was calculated for each gene set. CR, caloric restriction; FDR q value, False Discovery Rate; FWER P value, Family Wise Error
Rate; hTERT, human telomerase reverse transcriptase; hTERT DN, genes downregulated in hTERT-immortalized fibroblasts vs. non-
immortalized controls; NES, enrichment score normalized for differences in gene set size; NOM, nominal.
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study, we used DNA microarrays to compare skeletal
muscle transcripts between insulin-resistant PCOS pa-
tients and matched control subjects. We demonstrate a
significant downregulation of nuclear-encoded genes in-
volved in OXPHOS using two different approaches for
global pathway analysis. Quantitative real-time PCR anal-
ysis validated our findings and showed that downregula-
tion of PGC-1 is strongly associated with reduced
expression of OXPHOS genes. These findings provide
evidence for an association between insulin resistance and
impaired mitochondrial oxidative metabolism in skeletal
muscle of women with PCOS.
The most important finding of the study is that expres-
sion of nuclear-encoded genes involved in mitochondrial
oxidative metabolism is decreased in muscle of women
with PCOS. A similar decrease in OXPHOS gene expres-
sion has previously been reported in patients with type 2
diabetes and their first-degree relatives (20–22) but is, to
our knowledge, a novel finding associated with insulin
resistance in PCOS, where it is independent of obesity and
type 2 diabetes. The findings of a more pronounced
reduction in OXPHOS gene expression in patients with
type 2 diabetes compared with their first-degree relatives
(22) and that insulin treatment partly normalizes OXPHOS
gene expression in poorly controlled patients with type 2
diabetes (20) raise the possibility that impaired oxidative
metabolism is, at least in part, secondary to elevated
circulating glucose levels. However, a lower mitochondrial
ATP flux has been observed in insulin-resistant, glucose-
tolerant, first-degree relatives of patients with type 2
diabetes (19). In our study, all PCOS subjects had normal
A1C. Thus, although the etiological mechanisms of insulin
resistance in PCOS and first-degree relatives of patients
with type 2 diabetes may differ, this study provides further
support for an association between reduced OXPHOS
gene expression and insulin resistance in skeletal muscle
at an early stage before hyperglycemia develops. In skel-
etal muscle of obese subjects and patients with type 2
diabetes, mitochondrial dysfunction seems to be caused
by both a lower number of and decreased functional
capacity of mitochondria (7,17,18). Further studies are
needed to establish whether reduced OXPHOS gene ex-
pression is also associated with a lower content and
function of muscle mitochondria in PCOS. Transcriptional
profiling of ovarian tissues in PCOS did not show de-
creased expression of OXPHOS genes, suggesting that this
may be specific for muscle and not necessarily an etiolog-
ical factor in PCOS (33–35). Moreover, as in obesity and
type 2 diabetes, it remains to be determined whether
impaired OXPHOS in muscle of PCOS is a cause or
consequence of insulin resistance (7).
In addition to mitochondrial dysfunction, insulin resis-
tance in obese subjects, patients with type 2 diabetes, and
their first-degree relatives is characterized by a lower
proportion of oxidative, type 1 muscle fibers, reduced
maximal oxygen consumption (Vo2max), and increased
intramyocellular lipid content (7,8). Moreover, lipid oxida-
tion is impaired under basal conditions in obese and type
2 diabetic subjects (36,37). Recently, reduced Vo2max was
demonstrated in PCOS (4), and Mootha et al. (21) found
that the expression of OXPHOS genes was strongly corre-
lated with Vo2max. Although we did not measure Vo2max,
these findings indirectly support our hypothesis of an
impaired mitochondrial oxidative metabolism in muscle of
PCOS. To our knowledge, no data are available concerning
muscle fiber type composition, intramuscular lipid con-
tent, or leg lipid oxidation in PCOS. Using GSEA, we
observed that two sets of genes representing fatty acid
metabolism were the third and sixth most downregulated
pathways in PCOS. Thus, it is likely that abnormalities in
lipid metabolism also exist in muscle of PCOS patients.
However, further studies are needed to address whether
alterations in fiber type composition, increased lipid con-
tent, and impaired lipid oxidation in skeletal muscle are
also components of insulin resistance in PCOS.
Expression of nuclear- and mitochondrial-encoded mi-
tochondrial genes is thought to be coordinated by the
transcriptional coactivators PGC-1 and -1 through acti-
vation of NRF-1 and -2 (38). In skeletal muscle, PGC-1
also stimulates expression of the insulin-sensitive glucose
transporter GLUT4 and promotes an increased proportion
of oxidative, type 1 muscle fibers (38). Patti et al. (22)
provided evidence that downregulation of OXPHOS genes
in muscle of patients with type 2 diabetes and their
first-degree relatives is likely explained by reduced expres-
sion of PGC-1 and -1, although these observations were
made in separate study cohorts. They also found reduced
levels of NRF-1 but only in patients with type 2 diabetes,
indicating that this is not an early alteration associated
with insulin resistance. In the present study, we show that
decreased expression of PGC-1 is associated with re-
duced OXPHOS gene expression within the same cohort of
insulin-resistant women with PCOS, whereas the expres-
sion of PGC-1 and NRF-1 was unaltered. Moreover, we
provide evidence for a strong association between expres-
sion of PGC-1 and several subunits of the respiratory
complexes. The correlations observed were stronger in
control subjects than in PCOS subjects in whom a tight
correlation between only PGC-1 and the complex I
subunit NDUFA3 was seen. This could explain that, in
particular, genes representing subunits of the respiratory
complex I were downregulated in PCOS subjects. Our
results strongly suggest that downregulation of OXPHOS
genes are mediated mainly through reduced expression of
PGC-1 and further point to an important role for PGC-1
in impaired oxidative metabolism in skeletal muscle insu-
lin resistance in PCOS and the risk of type 2 diabetes in
these patients.
Studies of cultured fibroblasts and myotubes from PCOS
patients have provided evidence that constitutively en-
hanced serine phosphorylation of the insulin receptor and
IRS-1 could play an important role in the pathogenesis of
insulin resistance in PCOS (10–13). In cultured myotubes
(11) but not in fibroblasts (39), increased serine phosphor-
ylation of IRS-1 was associated with enhanced mitogenic
signaling. In skeletal muscle, which is the major site of
insulin-mediated glucose uptake, only a few significant
abnormalities have been demonstrated in muscle of
women with PCOS in vivo. This includes a transient
decrease in insulin stimulation of IRS-1–associated PI
3-kinase activity, increased phosphorylation of extracellu-
lar signal-regulated kinase 1/2, and increased IRS-2 protein
abundance (9,11). No differences in mRNA expression of
IRS-1 or IRS-2 were found (9). Although similar abnormal-
ities in proximal insulin signaling have been reported in
obesity and type 2 diabetes (7,8), it has been hypothesized
that the molecular mechanisms underlying insulin resis-
tance in PCOS differ from those seen in these conditions
(12). In the present study, we found that the insulin
signaling pathway, as defined by GenMAPP, was among
the 10 most up- and downregulated pathways in muscle of
women with PCOS. A number of genes mediating meta-
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bolic and mitogenic actions of insulin and modulators of
insulin action were dysregulated; however, in none of
these subpathways, the genes were uniformly up- or
downregulated. In recent studies of muscle transcripts,
dysregulation of the insulin signaling pathway was not
detected in patients with type 2 diabetes (20–22). This
indicates that changes in expression of genes or proteins
involved in insulin signaling, whether compensatory or
not, could play a greater role for insulin resistance in
skeletal muscle in PCOS than in type 2 diabetes. It also
emphasizes the need for further studies of expression and
activity of proteins known to mediate and modulate insu-
lin signaling in muscle of PCOS patients.
An intriguing finding of the study was that a calcium
pathway termed calcium regulation in cardiac cells was
significantly up- and downregulated (GenMAPP), and cal-
cium ion transporter activity was a significantly downregu-
lated gene ontology term in PCOS subjects. There is
increasing evidence supporting a modulating role for Ca2
influx, calmodulin, and Ca2/calmodulin-dependent pro-
tein kinase (CaMK) in insulin-stimulated glucose transport
in skeletal muscle (40–43). In mitochondria, Ca2 is
important for activation of key enzymes to enhance ATP
production, and an increase in cytosolic Ca2 and activa-
tion of CaMK also induce mitochondrial biogenesis and
GLUT4 expression via activation of different transcription
factors, including NRF-1 and -2, and the coactivator
PGC-1 (44–46). It is easy to infer that dysregulation of
Ca2 homeostasis could have a pronounced disturbing
effect on insulin-stimulated glucose disposal and mito-
chondrial function. Abnormal Ca2 homeostasis has been
reported in skeletal muscle of patients with type 2 diabetes
(47), and more recently, serum calcium was demonstrated
to be independently associated with insulin resistance
measured with euglycemic-hyperinsulinemic clamp (48).
Although similar abnormalities in muscle transcripts of
calcium pathway genes were not reported in studies of
patients with type 2 diabetes (20–22), it is too early to
conclude that the observed changes should play a unique
role for insulin resistance in skeletal muscle of PCOS
subjects. Further studies will be required to assess the
precise implication of Ca2 homeostasis in the pathogen-
esis of insulin resistance in PCOS.
In summary, using transcriptional profiling, we demon-
strate that insulin resistance in skeletal muscle of women
with PCOS is associated with reduced expression of genes
involved in mitochondrial oxidative metabolism and that
reduced expression of PGC-1 could play a role for these
abnormalities. Moreover, our data indicate that transcrip-
tional alterations in insulin signaling pathways, fatty acid
metabolism, and calcium homeostasis may contribute to
the potentially unique phenotype of insulin resistance in
patients with PCOS. Future studies focusing on the inter-
action between these pathways in skeletal muscle may
unravel the molecular mechanism of insulin resistance in
PCOS and help develop strategies to prevent the increased
risk of early onset of type 2 diabetes in these women.
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